This week marks the beginning of the 2016 Gastrointestinal Cancers Symposium in San Francisco. Smitha S. Krishnamurthi, MD, is a member of ASCO’s Cancer Communications Committee and a medical oncologist and Associate Professor of Medicine at the Case Western Reserve University. In this podcast, Dr. Krishnamurthi reports on some promising studies that will be presented.
A phase III study compared a short, 5-day radiation treatment with standard, 5-week radiation treatment in patients with advanced rectal cancer. It showed that for some patients, the shorter course of radiation could be more convenient and reduce side effects. [1:25]
A report from the RADIANT-4 study showed that everolimus (Afinitor) can slow the growth of neuroendocrine tumors of the gastrointestinal tract. These tumors are also called carcinoid tumors. Everolimus is a type of targeted therapy. [3:44]
Another study on neuroendocrine tumors of the gastrointestinal tract revealed that a new drug called 177Lutetium-DOTATATE slowed the growth of these tumors. 177Lutetium-DOTATATE combines hormone therapy and radiation therapy. [5:34]
This is a prerecorded audio podcast, and it can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Cancer.Net podcast page.